UBS maintains Sanofi at Neutral
An UBS analyst maintained Sanofi (EPA: SASY) Neutral at Neutral and a price target of $93.00. Prior to this rating, Sanofi had 15 buy ratings, 8 hold ratings, and 0 sell ratings. For...
Strong Buy
or
Sanofi ADR News & Analysis
-
-
Sanofi drug to treat 'smoker's lung' clears trial, says report
Sanofi added its "bold" decision to go without earlier-stage clinical COPD trials had shaved years off the development time
-
Sanofi and Regeneron Report Dupixent Met Endpoints in Phase 3 Trial for COPD
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically...
-
Regeneron and Sanofi Report Dupixent Shows Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (REGN) and Sanofi (NASDAQ:SNY) today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and...
-
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
Acer Therapeutics Inc (NASDAQ: ACER) announced topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to...
-
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Sanofi SA (NASDAQ: SNY) jumped the bandwagon with the other two insulin U.S. giants to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78%. Sanofi said it...
-
Sanofi cuts U.S. list price of Lantus, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
Sanofi (NASDAQ:SNY) cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insuranceSanofi...
-
Midday movers: First Republic, Illumina, Seagen and more
By Liz Moyer Investing.com -- Stocks are falling as the shutdown of SVB Financial Group (NASDAQ:SIVB) sends shockwaves through the banking sector. Here are the midday movers for March 10. ...
-
Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi
Sanofi SA (NASDAQ: SNY) has agreed to acquire Provention Bio Inc (NASDAQ: PRVB) for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds...
-
Influenza and COVID -19 Vaccine Market Report (2022 to 2030) - Pfizer Inc., AstraZeneca plc, Sanofi S.A., GlaxoSmithKline plc and Abbott Laboratories
Newark, New Castle, USA, March 13, 2023 (GLOBE NEWSWIRE) -- The global Influenza and COVID -19 vaccine market will be valued at 278.5 billion in 2030; the spike in cases of COVID pandemic...
-
Sanofi hones in on type 1 diabetes in $2.9 billion Provention Bio deal
By Ludwig Burger and Dina Kartit (Reuters) -France’s Sanofi has agreed to acquire Provention Bio for $2.9 billion to bolster its work on type 1 diabetes therapy and to strengthen its drug...
-
Sanofi to buy Provention Bio for $25 per share in deal worth $2.9 billion
Sanofi to buy Provention Bio for $25 per share in deal worth $2.9 billion
-
: Sanofi to buy Provention Bio in deal worth $2.9 billion
French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a...
-
Complement-Targeted Therapeutics Market Report (2022 to 2030) – Sanofi, Novartis AG, Pfizer Inc., Dianthus Therapies and Creative Biolabs
Newark, New Castle, USA, March 03, 2023 (GLOBE NEWSWIRE) -- The global complement-targeted therapeutics market is expected to grow at a CAGR of 8.9% from 2022 to 2030, owing to the rising...
-
: Eli Lilly CEO says $35 for monthly insulin ‘should be the new standard in America’
Eli Lilly & Co. said Wednesday it's capping out-of-pocket insulin costs at $35
-
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The...
-
Peptide Therapeutics Market Report (2022 to 2030) - Pfizer Inc., Eli Lilly and Company, Sanofi S.A, GlaxoSmithKline plc and Bristol-Myers Squibb Company
Newark, New Castle, USA, March 01, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, "Global Peptide Therapeutics Market by Application (Metabolic, Cardiovascular...
-
Hold Sanofi India; target of Rs 6270: ICICI Direct
ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6270 in its research report dated February 27, 2023.
-
Buy Sanofi India, target price Rs 6200: Sharekhan by BNP Paribas
Sanofi India, incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 13232.93 Crore) operating in Pharmaceuticals sector.
-
Hold Sanofi India, target price Rs 6270: ICICI Direct
Sanofi India, incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 13505.73 Crore) operating in Pharmaceuticals sector.
-
Broker’s Call: Sanofi India (Buy)
Centrum Broking
-
Sanofi India shares clock biggest intraday gain in 7 months on robust bottomline
Elara Capital gave a Buy call for the stock as it sees an upside potential of 26%
-
Buy Sanofi India; target of Rs 6200: Sharekhan
Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 6200 in its research report dated February 24, 2023.
-
FDA Approves Sanofi's Hemophilia A Therapy Offering Significant Bleed Protection
The FDA approved Sanofi SA's (NASDAQ: SNY) Altuviiio, previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy. Altuviiio is indicated...
-
Sanofi India shares rise 5% on strong Q4 earnings
Sanofi India stock opened with a gain of 4.47% at Rs 5600 today. Later, the stock touched an intraday high of Rs 5614.9, rising 4.75% on BSE.
-
Dow Jones Newswires: Sanofi gets FDA approval for hemophilia drug
The French pharmaceutical company FR:SAN said this is the first approval of the drug, previously referred to as efanesoctocog alfa, and that regulatory submission in the European Union is...
-
Sanofi India shares gain as Oct-Dec net profit rises sharply
Sanofi India has also announced a final dividend of Rs 194 per share and a second special dividend of Rs 183 per share
-
Sanofi India gains as Q4 PAT jumps 45% YoY
Sanofi India rallied 3.97% to Rs 5,573.05 after the company's net profit surged 44.8% to Rs 130.9 crore in Q4 CY22 from Rs 90.40 crore in Q4 CY21.
-
Sanofi India standalone net profit rises 44.80% in the December 2022 quarter
Sales decline 2.33% to Rs 671.90 crore
-
Buzzing Stocks: Mahindra Lifespace, Bharat Forge, Sanofi India, and others in news today
Stocks to Watch: Check out the companies making headlines before the opening bell today.
-
Sanofi India to pay total dividend for FY 2022
On or after 22 May 2023
-
Johnson & Johnson names ex-Sanofi executive as pharma, R&D vice president
(Reuters) – Johnson & Johnson said on Monday John Reed will take the role of executive vice president of pharmaceuticals, research and development, effective April 3.
-
Connected Healthcare Market Report (2022 to 2030) - Cerner Corporation, Apple Inc., Fitbit Inc., IBM Corporation, SAP, Sanofi and McKesson Corporation
Newark, New Castle, USA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global connected healthcare market is expected to clock US$...
-
Regeneron shares rise as eczema drug sales help drugmaker post Q4 earnings beat
By Scott Kanowsky Investing.com -- Shares in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rose on Friday after the drugmaker posted better-than-expected earnings in the fourth quarter...
-
Sanofi ADR earnings beat by $0.79, revenue fell short of estimates
Investing.com - Sanofi ADR (NASDAQ: SNY) reported fourth quarter EPS of $1.71, $0.79 better than the analyst estimate of $0.92. Revenue for the quarter came in at $10.72B versus the...
-
Dow Jones Newswires: Sanofi profit narrowly beats forecasts, sees stronger earnings growth in 2023
The French pharma majorFR:SAN SNY reported net profit of 1.46 billion euros ($1.59 billion) for the quarter, on sales that grew to EUR10.73 billion from EUR9.99 billion in the previous...
-
Dow futures trade lower as tech earnings disappoint, Apple sheds 2.8%
By Oliver Gray Investing.com - U.S. stock futures were trading lower during Thursday's evening deals, after major benchmark averages finished mixed as investors grew cautious after a slew...
-
Jobs report, Sanofi earnings, Cigna results: 3 things to watch
By Liz Moyer Investing.com -- Tech stocks got a huge lift from Meta Platforms' (NASDAQ:META) unexpectedly strong showing in the fourth quarter, pushing the Nasdaq up over 3% during the day,...
-
Sanofi offers VRS to 800 employees at two units in Telangana
A Sanofi spokesperson told ET that a glut of supplies added during Covid-19 and the struggle to win contracts from Unicef for its critical 5-in-1 pediatric vaccine Shan5 forced the company...
-
Critical Care Antiarrhythmic Drugs Market Report (2022 to 2030) - Pfizer Inc., Bayer AG, Novartis AG, Mylan N.V., Sanofi S.A. and Johnson & Johnson
Newark, New Castle, USA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The global "Critical Care Antiarrhythmic Drugs Market Size" is expected to rise with an impressive CAGR and generate the highest...
-
Amgen secures $28.3 billion deal to buy Horizon Therapeutics
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
-
Dow futures rise 45 pts; rebounding ahead of Fed, CPI data
By Peter Nurse Investing.com -- U.S. stocks are seen opening marginally higher Monday, starting an important week that includes consumer inflation data and the final Federal Reserve...
-
Amgen to acquire Horizon for $26 billion as Sanofi drops bid - report
By Senad Karaahmetovic Amgen (NASDAQ:AMGN) has agreed to acquire Horizon Therapeutics (NASDAQ:HZNP), according to Bloomberg News. Amgen agreed to pay $116.5 for each HZNP share, valuing the...
-
Sanofi shares rise after French drugmaker ditches Horizon deal talks
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) rose on Monday after the French drugmaker backed out of its plans to bid for biotech company Horizon Therapeutics PLC...
-
European stocks weaken; caution ahead of central bank meetings
By Peter Nurse Investing.com - European stock markets retreated Monday, with investors cautious ahead of policy-setting meetings from the likes of the Federal Reserve and the European...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
